The efficacy of omarigliptin in type 2 diabetic patients

The efficacy of omarigliptin in type 2 diabetic patients - The efficacy of omarigliptin in type 2 diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026700

Enrollment

Registered

2017-03-28

Start date

2017-03-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Naive cases for DPP-4 inhibitor Patients with poor glycemic control on conventional therapy 2. Additional administration of omarigliptin Patients with poor glycemic control with drug treatment except for DPP-4 inhibitor 3. Cases whose treatment is changed from other DPP-4 inhibitors Criteria of poor glycemic control: HbA1c level exceeding 7.0% and/or glycated albumin level exceeding 21.0%

Exclusion criteria

Exclusion criteria: Patients having infectious diseases, thyroid disease, or malignant tumors. Patients being treated with steroids and changing the dosage. Patients considering not eligible for this trial by attending doctors due to any medical reasons.

Design outcomes

Primary

Measure	Time frame
The change in postprandial plasma glucose, glycated albumin and HbA1c three months after administration of omarigliptin	—

Secondary

Measure	Time frame
1. Body wight, blood pressure, body composition 2. Serum C peptide 3. Incidence of adverse events 4. Incidence of hypoglycemia 5. Medication adherence, QOL	—

Countries

Japan

Contacts

Public ContactMachiko Komatsu

Kawashima Hospital, Social Medical Corporation Kawashima Hospital Group Department of diabetes mellitus

machikomatsu@r7.dion.ne.jp088-631-0110

Outcome results